F. Fakhouri, J. Zuber, V. Fremeaux-bacchi, and C. Loirat, Haemolytic uraemic syndrome, Lancet, vol.390, pp.681-696, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02155934

T. S. Jokiranta and . Hus, Blood, vol.129, issue.21, pp.2847-2856, 2017.

C. Masias, S. Vasu, and S. R. Cataland, None of the above: thrombotic microangiopathy beyond TTP and HUS, Blood, vol.129, issue.21, pp.2857-2863, 2017.

C. M. Legendre, C. Licht, and P. Muus, Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med, vol.368, issue.23, pp.2169-2181, 2013.

A. Cremer, F. Amraoui, and G. Y. Lip, From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency, J Hum Hypertens, vol.30, issue.8, pp.463-466, 2016.

G. Mancia, R. Fagard, and K. Narkiewicz, ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 8. van den Born BJ, van der Hoeven NV, vol.34, pp.862-866, 2005.
URL : https://hal.archives-ouvertes.fr/hal-02042310

V. Fremeaux-bacchi, F. Fakhouri, and A. Garnier, Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, CJASN, vol.8, issue.4, pp.554-562, 2013.

C. P. Larsen, J. D. Wilson, A. Best-rocha, M. L. Beggs, and R. A. Hennigar, Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy, Mod Pathol, vol.31, issue.3, pp.488-494, 2018.

M. Noris, J. Caprioli, and E. Bresin, Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, CJASN, vol.5, issue.10, pp.1844-1859, 2010.

S. Timmermans, A. , M. A. Potjewijd, and J. , C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension, JASN, vol.29, issue.8, pp.2234-2243, 2018.

P. Vieira-martins, E. Sissy, C. Bordereau, P. Gruber, A. Rosain et al., Defining the genetics of thrombotic microangiopathies, Transfus Apher Sci, vol.54, issue.2, pp.212-219, 2016.

S. Richards, N. Aziz, and S. Bale, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference, vol.17, pp.539-551, 2015.

M. C. Foster, J. Coresh, and M. Fornage, APOL1 variants associate with increased risk of CKD among, African Americans. JASN, vol.24, issue.9, pp.1484-1491, 2013.

K. Hovinga, J. A. Heeb, S. R. Skowronska, M. Schaller, and M. , Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, JTH, vol.16, issue.4, pp.618-629, 2018.

V. Fremeaux-bacchi, E. J. Kemp, and J. A. Goodship, The development of atypical haemolyticuraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts, J Med Genet, vol.42, issue.11, pp.852-856, 2005.

A. J. Osborne, M. Breno, and N. G. Borsa, Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy, J Immunol, vol.200, issue.7, pp.2464-2478, 2018.

R. O. Mathew, A. Nayer, and A. Asif, The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy, JASH, vol.10, issue.4, pp.352-359, 2016.

P. N. Chander, R. Rocha, J. Ranaudo, G. Singh, A. Zuckerman et al., Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP, JASN, vol.14, issue.8, pp.1990-1997, 2003.

E. Negishi, N. Fukuda, and T. Otsuki, Involvement of complement 3 in the salt-sensitive hypertension by activation of renal renin-angiotensin system in spontaneously hypertensive rats, Am J Physiol Renal Physiol, vol.315, issue.6, pp.1747-1758, 2018.

Z. D. Bekassy, A. C. Kristoffersson, J. Rebetz, R. Tati, A. I. Olin et al., Aliskiren inhibits renin-mediated complement activation, Kidney international, vol.94, issue.4, pp.689-700, 2018.

V. Raghunathan, S. K. Sethi, and M. A. Dragon-durey, 25. van den Born BJ, Koopmans RP, van Montfrans GA. The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension, Indian J Nephrol, vol.27, issue.2, pp.900-906, 2007.

P. Romagnani, G. Remuzzi, and R. Glassock, Chronic kidney disease, Nat Rev Dis Primers, vol.3, p.17088, 2017.

F. Fakhouri, M. Fila, and F. Provot, Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation, CJASN, vol.12, issue.1, pp.50-59, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02155912